UPDATE: BioLine Rx Q2 EPADS $(1.00) Beats $(1.20) Estimate, Sales $304.000K Miss $924.000K Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings BeatsEarnings MissesNews
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.20) by 16.67 percent. The company reported quarterly sales of $304.000 thousand which missed the
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.20) by 16.67 percent. The company reported quarterly sales of $304.000 thousand which missed the analyst consensus estimate of $924.000 thousand by 67.10 percent. This is a 94.36 percent decrease over sales of $5.393 million the same period last year.